{
    "Trade/Device Name(s)": [
        "Bionexia Single and Multi-Strip Cassette/Dipstick DOA Screen Panels",
        "ADT's BionexiaM Single and Multi-Strip Cassette/Dipstick DOA Screen Panels"
    ],
    "Submitter Information": "Applied DNA Technologies Inc.",
    "510(k) Number": "K080467",
    "Predicate Device Reference 510(k) Number(s)": [
        "K022589",
        "K013380"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LDJ",
        "DIO",
        "DNK",
        "DKZ",
        "DJC",
        "DIS",
        "JXM",
        "DJR",
        "LFG",
        "DJG",
        "LCM"
    ],
    "Summary Letter Date": "November 11, 2008",
    "Summary Letter Received Date": "November 13, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3870",
        "21CFR862.3250",
        "21CFR862.3640",
        "21CFR862.3100",
        "21CFR862.3610",
        "21CFR862.3150",
        "21CFR862.3170",
        "21CFR862.3620",
        "21CFR862.3910",
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Amphetamine Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Barbiturate",
        "Benzodiazepines",
        "Cocaine",
        "Marijuana (THC)",
        "Methamphetamine",
        "Methadone",
        "Morphine",
        "Phencyclidine",
        "Nortriptyline",
        "Ecstasy (MDMA)",
        "Buprenorphine",
        "EDDP"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Colloidal gold based chromatographic immunoassay"
    ],
    "Methodologies": [
        "Chromatographic immunoassay"
    ],
    "Submission Type(s)": [
        "Panel",
        "Cassette",
        "Dipstick"
    ],
    "Document Summary": "FDA 510(k) summary for Bionexia Single and Multi-Strip Cassette/Dipstick DOA Screen Panels for rapid, qualitative detection of multiple drugs of abuse in human urine using chromatographic immunoassay.",
    "Indications for Use Summary": "Qualitative and simultaneous detection of up to thirteen drugs of abuse in human urine to assist health care professionals, including at point-of-care sites, in determination of drug compliance; results are preliminary and require confirmatory testing.",
    "fda_folder": "Toxicology"
}